Background Masculinizing hormonal treatment in transgender men has the potential to increase the level of androgens at end organs, including the pilosebaceous unit. Androgen-induced sebocyte growth and differentiation, sebum production and infundibular keratinization may underlie the development of acne vulgaris among patients receiving this therapy. Objectives The aim of this article is to familiarize dermatologists with the sensitivities and challenges of treating acne in transgender male individuals. Methods This review article discusses the pathogenesis and treatment of acne in transgender men on testosterone therapy and highlights the unique considerations in treating this underserved patient population. Results Despite the incidence of treatment-related acne and the unique considerations in treating transgender men, studies addressing this topic among this patient population are limited. Conclusions Generally, the standard guidelines for the treatment of acne can be followed in treating these patients; however, several medical, social and psychological factors should be considered.
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What's already known about this topic?
• Acne vulgaris is a known side-effect of masculinizing hormonal therapy.
• Treatment with isotretinoin in these patients poses several ethical challenges.
What does this study add?
• This review article discusses the pathogenesis and treatment of acne in transgender men on testosterone therapy.
• This article highlights the unique considerations in treating this underserved patient population.
Acne is a common inflammatory skin disease affecting the pilosebaceous units of the skin. The pathogenesis of this condition is classically attributed to follicular hyperkeratinization, microbial colonization with Propionibacterium acnes, increased sebum production and inflammation. The interrelationship of these four factors has been the focus of more recent research, which has also been extended to explore other areas such as diet, genetics and oxidative stress. 1 Lesions can have a significant psychosocial impact, resulting in higher rates of depression, suicidal ideation and body image issues among patients. 2 This effect may be especially concerning in lesbian, gay, bisexual, transgender, queer or questioning + other (LGBTQ+) patients, whose baseline elevations in depression and challenges with body image may contribute to the higher rates of depression among those with acne. 3 These potential issues are particularly concerning in the context of transgender men, for whom exogenous androgens may be first-line treatments for gender dysphoria, i.e. the distress that may accompany the incongruence between one's experienced or expressed gender and one's assigned gender. 4 Exogenous testosterone can exacerbate acne, among other hair and skin issues, prompting patients to seek dermatological care. Despite the increasing awareness of transgender patients within the medical community, a substantial gap in their care remains. This is, in part, due to social and economic marginalization, but the lack of medical experience working with this population still plays a substantial role. 5 Therefore, the aim of this article is to promote understanding for the purposes of counselling and treating transgender men who present with acne as a result of masculinizing hormonal therapy.
Masculinizing hormonal therapy
The term 'transgender' describes a wide range of identities in which an individual's gender identity and/or expression differs from that which the individual was assigned at birth. In this article, we use the term 'transgender' to include patients who may identify outside the typical binary of 'male' and 'female', for example 'genderqueer' or 'agender'. Depending on the patients' goals, hormonal therapy and gender-affirming procedures, both noninvasive and surgical, can improve the alignment of these patients' physical characteristics with the gender that they choose to express. Treatment with testosterone, the mainstay of masculinizing hormonal therapy, has several goals. One of these goals is to produce the internal feeling of masculinity that the hormone creates; another is to promote the development of masculine secondary sexual characteristics and to improve societal perceptions of these patients as male, which ultimately serves to improve their sense of safety, self-confidence and symptoms of gender dysphoria. 6 Some patients are not trying to be perceived as male, but rather as more masculine or androgynous.
Testosterone stimulates male-patterned hair growth and body contour, 7 causing suppression of oestrogen and subsequent cessation of uterine bleeding. 8 Currently, there is a lack of consensus on the ideal starting or maintenance dosages or preparations of testosterone; however, dosages usually do not exceed those used in nontransgender male patients. 9 Therapy often begins with an initiation period at a low dosage followed by a gradual increase to an adult male replacement dosage. 6 Testosterone is most often given intramuscularly, or topically, but can be given orally, buccally, nasally or via subcutaneous implants. 6 Physiological role of androgens on sebum production and acne
The exact mechanism of testosterone in the pathogenesis of acne has yet to be fully elucidated. Testosterone affects the sebaceous gland primarily through local conversion to dihydrotestosterone (DHT) via type-1 5-a reductase. 10 Among all androgens, DHT binds cytoplasmic androgen receptors with the highest affinity; 11 these receptors are expressed most abundantly in sebocytes, eccrine sweat epithelium and dermal papilla cells. 12, 13 In sebocytes, androgens primarily affect sebocyte proliferation. Androgens, fatty acids and linoleic acid act via peroxisome proliferator-activated receptor-c receptors to regulate epidermal growth and sebocyte differentiation. Increased sebum production plays a principal role in the pathogenesis of acne vulgaris, as holocrine sebum secretions and shed keratin accumulate behind desquamated cells in the upper follicular canal.
14 Proliferation of P. acnes upregulates the host immune response causing the typical inflammatory lesions seen in acne. 10 However, the importance and order of these steps are controversial. 15 The differential expression of androgen receptors is thought to mediate the distribution of acne lesions. In contrast to Uzones, T-zones of the facial skin express higher levels of androgen receptor protein and mRNA, 16 which mirrors the distribution of acne observed clinically.
Effects of masculinizing hormones on acne
In one study of 20 transgender men initiating testosterone treatment, 17 the prevalence of facial acne increased from 35%
at baseline to 82% after only 6 months; on the back and/or chest, acne increased from 15% at baseline to 88%. After 1 year, acne lesions persisted on the face in 55% of patients and on the back and/or chest in 50% of patients. The majority of these acne lesions were considered mild on the Global Acne Grading System, 20% were moderate and none were severe. 17 The same study also evaluated an additional 50 transgender men treated with testosterone for an average of 9Á9 years. Using the same Global Acne Grading System, the majority (63%) had mild acne lesions, 6% had moderate acne and 31% had no active lesions. Lesion severity was unrelated to age, sebum production, duration of treatment or type of hormonal therapy. The absence of a correlation between lesion severity and serum levels of luteinizing hormone, testosterone, DHT, oestradiol or sex hormone-binding globulin demonstrates the variable end organ response. 17 A second prospective study 7 of 17 transgender men used the Leeds classification 18 to characterize acne severity. After 4 months, acne developed on the face and back of 10 and 11 patients, respectively. After 1 year, Leeds scores were higher for lesions on the back than those on the face. However, sebum production on the back was paradoxically lower than on the face. Overall, sebum production increased in all patients and was independent of local levels of 3 a-androstanediol glucuronide, which is the major metabolite of DHT. These studies suggest that the severity of acne peaks within the first 4 months of treatment. Although gradual improvement is noted within the first year, acne can be persistent, lasting years after the initiation of testosterone therapy. Individual severity of acne is variable, with most patients experiencing milder lesions. Acne tends to be most prominent on the back and chest, an area that is already one of the greatest sources of dissatisfaction among transgender men. 19, 20 Lesion severity is unrelated to sebum production, demonstrating the importance of other factors in the pathogenesis of acne and the immunomodulatory effects of testosterone.
Treatments
In general, the standard guidelines 21 for the treatment of acne may be followed for transgender men; however, healthcare providers must consider several medical, social and psychological factors when treating this population. As in the treatment of cisgender individuals (nontransgender individuals), topical therapies and systemic antibiotics are considered first-line treatments for acne. These treatments may be insufficient for complete treatment of androgen-induced acne lesions, and escalation of treatment is often required. 22, 23 Isotretinoin remains a valuable treatment option for patients who fail to respond to these therapies and may be used as a first-line therapy in patients with severe acne. Systemic isotretinoin may be particularly effective in treating testosteroneinduced acne via antagonism of the androgen's effects at the level of the sebaceous gland, inhibiting sebocyte proliferation and differentiation, resulting in atrophy and decreased sebum production. [24] [25] [26] [27] In practice, isotretinoin is effective in patients receiving masculinizing therapy, though multiple courses of treatment may be required. 28 The treatment algorithm in transgender men and cisgender women show some similarities, with the exception of some key agents. Hormonal therapy is likely to interact with the desired effects of testosterone in transgender men; therefore, a discussion with the physician overseeing the patient's masculinizing hormonal treatment should take place prior to initiating any hormone-based acne treatment. Low-dose ethinylestradiol in combination with either norgestimate, norethindrone or drospirenone, which are approved by the U.S. Food and Drug Administration (FDA) for the treatment of acne in cisgender women, 21 requires careful planning and extensive discussion before use in this patient population. Other forms of hormonal contraceptive, such as the birth control patch (ethinylestradiol plus norelgestromin), intravaginal ring (etonogestrel/ethinylestradiol) and androgen receptor modulating agents (spironolactone or flutamide), are used effectively as off-label treatments for hormonal acne in cisgender women, but may prove difficult to use in transgender men. If hormonal agents are used, treatment should be postponed until the masculinizing effects of hormonal therapy have reached their maximal effect, which may not occur for more than 2 years after the initiation of testosterone. 20 In our experience, transgender men rarely elect to use these agents unless indicated for reasons unrelated to contraceptive management.
Combining testosterone with some acne medications may lead to other potential adverse effects. The theoretical risk of hepatotoxicity with isotretinoin or tetracyclines may be amplified by the adverse liver effects associated with exogenous testosterones. Cholestatic jaundice, peliosis hepatis and haematoma were historically associated with oral preparations using 17-alkylated androgens, 29, 30 which are therefore no longer used. Nonetheless, frequent monitoring is still warranted in patients receiving a combination of any formulation of testosterone with isotretinoin. 31 Current evidence does not support the association between isotretinoin and depression, but prescribing physicians should continue to monitor for depressive symptoms for several reasons. Although gender-affirming treatment can improve the symptoms of depression, 32 rates in transgender individuals remain higher than those of cisgender individuals. In a survey of 6450 transgender and gender-nonconforming participants, 41% of respondents reported attempting suicide. 5 These concerning statistics must also be weighted with the strong association of acne and depression 33 and evidence that suggests positive effects of isotretinoin on symptoms of anxiety and depression. The risk of medication teratogenicity is another important consideration in the treatment of acne in transgender men. As masculinizing hormonal therapy has not been evaluated in terms of its efficacy as a contraceptive, transgender male patients are still considered to be at risk for pregnancy 34 even if they are not menstruating. 35 It is important to note that gender identity does not imply sexual orientation or behaviour. For this reason, careful history and counselling should be performed prior to initiation of any acne treatment with potential for teratogenicity, such as retinoids, tetracyclines, among others. Despite this risk, it can be challenging to approach the topic of teratogenicity with this patient population. Creating an inclusive environment for all gender identities can set the foundation for an open physician-patient relationship so that patients of all gender identities may be more open to disclosing their gender identity and pregnancyrelated issues. Furthermore, tools developed to prevent these teratogenic side-effects in cisgender women are not designed with transgender patients in mind; they can result in confusion for both patients and physicians and have the potential to result in mismanagement of care. For example, the iPLEDGE risk management programme developed by the FDA for the prevention of the teratogenic effects of isotretinoin requires patients to register as either male or female; such binary terms are incongruent with the range of gender identities with which patients can identify. Under the current requirements, transgender men who are of childbearing potential (i.e. have ovaries and a uterus) must register as female patients of reproductive potential. If transgender men do not disclose to the dermatologist that they are transgender, they may be improperly monitored unbeknownst to the prescribing dermatologist. Patients who register as female are required to take monthly pregnancy tests, and ensure that they are using at least two forms of birth control or remain abstinent. Some define abstinence as refraining from receptive vaginal intercourse, which may apply to some transgender men. This strictly binary system has the potential to exacerbate gender dysphoria and further the social disparities that burden this population in the healthcare system. [36] [37] [38] Physicians may be hesitant to prescribe this treatment, and patients may be less likely to agree to it. Many advocates call for gender to be removed completely from the iPLEDGE system, focusing the discussion of teratogenicity on the patient's reproductive potential. Early case series describing delayed wound healing and keloid formation have caused some patients to defer treatment with isotretinoin until they undergo top surgery (bilateral mastectomy with masculinizing chest wall reconstruction) and/or bottom surgery (total hysterectomy and salpingooophorectomy, vaginectomy, urethroplasty, scrotoplasty, metoidioplasty and/or phalloplasty). For patients who may prefer to undergo these surgeries after acne treatment with isotretinoin, current recommendations suggest delaying such procedures until the patient has been off isotretinoin for 6-12 months. 39 A discussion of surgical plans should be part of pretreatment counselling. Chest binding may also exacerbate acne in some patients. To achieve a more masculine chest contour, patients may wrap their chests with elastic bandages, Ace wrap, plastic wrap, duct tape, sports bras or commercial binders. 40 Binding can cause numerous dermatological sequelae, particularly when worn for longer durations. 41 Dermatologists may counsel patients to take days off, use sports bras when possible and practice good skin hygiene.
Conclusion
Acne is a common side-effect of the masculinizing hormonal therapies used to treat gender dysphoria in transgender male patients. For this reason, dermatologists can play an important role in the management of these patients. Although the options for treating acne are similar to those used in cisgender patients, several medical, social and psychological considerations must be noted when treating these patients. An understanding of the unique needs of the transgender population will continue to become increasingly important as improved societal acceptance allows transgender men and women to live more easily in accordance with their affirmed gender identity and expression.
